Stigmatization and Preferences in Monkeypox Vaccine Regimens
Archives of Sexual Behavior · 2024
DOI: 10.1007/s10508-024-02975-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Sexual Behavior, 2024. Verfasst von Yi-Hsuan Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Mpox, Monkeypox. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A significant monkeypox (mpox) outbreak occurred in 2022, particularly involving sexual and gender minority (SGM) groups. Stigma and misperceptions have led to fear of being labeled a member of the SGM group when obtaining immunization for mpox. We hypothesized that the most recommended injection site, intradermal injection in the forearm, stresses stigmatization. We conducted an online survey in a medical center in Taiwan between May 2023 and June 2023 among adults who were going to receive the second preexposure vaccination. The questionnaire comprised questions about physical and psychological impacts of the first mpox vaccination and the preference for the second vaccination location and factors influencing the preference. A total of 2,827 individuals (98.4% male) completed the questionnaires. Intradermal injection in the forearm was related to greater physical and psychological impacts of local adverse events, especially discoloration. "Beauty," "scar," and "others' view" were the most significant factors influencing preference for vaccination regimens. Compared to intradermal injection in the forearm, subjects who cared about "others' views" were likely to prefer vaccination in the deltoid. The odds ratio for preferring intradermally injection in the deltoid over in the forearm was 1.88 (95% CI 1.38-2.56). The odds ratio for preferring subcutaneous injection in the deltoid over intradermally injection in the forearm was 1.69 (95% CI 1.23-2.32). The odds ratio for preferring intradermally injection in the deltoid regardless of the route over intradermally injection in the forearm was 2.11 (95% CI 1.53-2.92). This study demonstrated the adverse events of different mpox vaccination regimens and their association with stigma. Recognizing the factors affecting the preference for mpox vaccine regimens is crucial for easing the mental stress of vaccinee.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, 7 Zhongshan South Road, Taipei, 100, Taiwan.
- Training Center for Travel Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Family Medicine, National Taiwan University Hospital, Bei-Hu Branch, Taipei, Taiwan.
- Department of Family Medicine, College of Medicine and Hospital, National Taiwan University, 7 Zhongshan South Road, Taipei, 100, Taiwan. biopsycosocial@gmail.com.
- Training Center for Travel Medicine, National Taiwan University Hospital, Taipei, Taiwan. biopsycosocial@gmail.com.
ORCID-Profile: Chia-Wen Lu
Zitieren
APA
Shen, Y. H., Chang, H. H., Tou, C. Y., Lee, Y. C., Lee, Y. H., Cheng, S. Y., Huang, K. C., & Lu, C. W. (2024). Stigmatization and Preferences in Monkeypox Vaccine Regimens. Archives of Sexual Behavior. https://doi.org/10.1007/s10508-024-02975-6
Vancouver
Shen YH, Chang HH, Tou CY, Lee YC, Lee YH, Cheng SY, et al. Stigmatization and Preferences in Monkeypox Vaccine Regimens. Archives of Sexual Behavior. 2024. doi:10.1007/s10508-024-02975-6
BibTeX
@article{Shen2024,
author = {Shen, Yi-Hsuan and Chang, Hao-Hsiang and Tou, Chiao-Yun and Lee, Yi-Chen and Lee, Yi-Hsuan and Cheng, Shao-Yi and Huang, Kuo-Chin and Lu, Chia-Wen},
title = {Stigmatization and Preferences in Monkeypox Vaccine Regimens},
journal = {Archives of Sexual Behavior},
year = {2024},
doi = {10.1007/s10508-024-02975-6}
}
EUVIMED